"Androxal presents several potential advantages including oral dosing, fewer side effects, and...


"Androxal presents several potential advantages including oral dosing, fewer side effects, and preservation of fertility," Bank of America says, initiating Repros Therapeutics (RPRX +3.3%) at Buy with a $25 price target. Analyst Steve Byrne sees peak 2022 sales of $450M for the low testosterone treatment, although there are potential risk factors including "a remaining phase 3 read-out" and the company's lack of "commercialization experience."

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs